Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation | Zendy

Shauna L. Hillman | Zendy; Sumithra J. Mandrekar | Zendy; Brian M. Bot | Zendy; Ronald P. DeMatteo | Zendy; Edith A. Perez | Zendy; Karla V. Ballman | Zendy; Heidi Nelson | Zendy; Jan C. Buckner | Zendy; Daniel J. Sargent | Zendy

Open Access

Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation

Author(s) -

Shauna L. Hillman,

Sumithra J. Mandrekar,

Brian M. Bot,

Ronald P. DeMatteo,

Edith A. Perez,

Karla V. Ballman,

Heidi Nelson,

Jan C. Buckner,

Daniel J. Sargent

Publication year - 2010

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2009.27.4282

Subject(s) - medicine , placebo , adverse effect , clinical trial , randomized controlled trial , attribution , cancer , imatinib , oncology , surgery , alternative medicine , pathology , psychology , social psychology , myeloid leukemia

In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution adds value to the interpretation of AE data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research